Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amifostine, Topotecan, and Cytarabine for Poor Risk MDS
NCT00003827Phase 2Unknown
- Sponsor
- ALZA Corporation
- Start
- Jan 1999
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amifostine in myelodysplastic syndromes (MDS), sponsored by ALZA Corporation. Primary endpoint: Toxic effects of amifostine, topotecan, and cytarabine. Status: unknown.
02
Drugs
amifostine
03
Conditions
myelodysplastic syndromes (MDS)
Beyond the preview
Go deeper on NCT00003827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003827.